Dian Kortleve

Dian Kortleve

Auto-generated profile, based on publicly available information

Dian Kortleve

Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2022 in Trends in Immunology
Verified
Journal Article
Open access
DKDian Kortleve
Dian Kortleve
RCRui M.L. Coelho
Rui M.L. Coelho
DHDora Hammerl
Dora Hammerl
RDReno Debets
Reno Debets
Cancer germline antigens (CGAs) are expressed in immune-privileged germline tissues, while epigenetically silenced in somatic tissues. CGAs become re-expressed in tumors and can promote oncogenesis. Tumors prominently exploit mechanisms similar to those in germline tissues to shield from immunosurveillance. We hypothesize that CGAs contribute towards tumor escape from immune effector CD8+ T cells. For illustrative purposes, we assessed the co-presence or -absence of CGAs with these cells in multiple tumor types. Considering a broad array of CD8+ T cell evasive mechanisms, we exemplify the co-occurrence of gene transcripts of eight CGAs with those of adhesion molecules, endothelial cells, and/or the Wnt pathway. We present a novel concept of CGAs and their association with CD8+ T cell evasion, which may be relevant for future immunotherapeutic interventions.

21 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy van Brakel
Mandy van Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Triple-negative breast cancer (TNBC) has an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. Human leukocyte antigen-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCR) from naïve repertoires. Following gene introduction into T cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize noncognate epitopes from alternative source proteins. Notably, this TCR-mediated killing of three-dimensional (3D) tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T cells as a treatment for the vast majority of patients with TNBC. Significance: Metastatic TNBC has a dismal prognosis. This study discovers Ropporin-1 as a target for T-cell therapy for most patients. The selected TCR is highly specific and sensitive in advanced models, and preclinical testing shows that the T-cell product expressing this TCR, manufactured according to good manufacturing practice, has favorable safety and potency.

1 December 2022 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SMshweta mahajan
shweta mahajan
DKDian Kortleve
Dian Kortleve
RDReno Debets
Reno Debets
DHDora Hammerl
Dora Hammerl
Detection and amplification of epitope-specific T cells hold great promise for diagnosis and therapy of cancer patients. Currently, measurement and retrieval of epitope-specific T cells is hampered by limited availability of patients’ biomaterials and lack of sensitive and easy-to-implement T cell priming and expansion. We have developed an in vitro T cell amplification system starting from healthy donor blood and tested different subsets and ratios of autologous T cells and APCs as well as the resting period between amplification cycles. We demonstrated in 10 different donors significantly enhanced frequency of T cells specific for MelanA/HLA-A2, which relied on coculturing of naive T cells and CD11c+ dendritic cells in a 1:1 ratio followed by three weekly amplification cycles using the effluent of the naive T cell sort as APCs, a 24-h rest period prior to every reamplification cycle, and IFN-γ production as a readout for epitope-specific T cells. Using this system, MelanA/HLA-A2–specific T cells were enriched by 200-fold, measuring up to 20–60% of all T cells. We extended this system to enrich NY-ESO-1/HLA-A2– and BMLF-1/HLA-A2–specific T cells, examples of a cancer germline Ag and an oncoviral Ag differing in their ability to bind to HLA-A2 and the presence of specific T cells in the naive and, in case of BMLF-1, also the Ag-experienced repertoire. Collectively, we have developed a sensitive and easy-to-implement in vitro T cell amplification method to enrich epitope-specific T cells that is expected to facilitate research and clinical utility regarding T cell diagnosis and treatments. Key Points Easy-to-implement in vitro amplification of specific T cells from healthy donors is described. Robust amplification of viral- or tumor-specific T cells with low frequencies in blood is shown. Parameters required for amplification of epitope-specific T cells are identified.

11 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy V Brakel
Mandy V Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Triple-negative breast cancer (TNBC) shows an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T-cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. HLA-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCRs) from naïve repertoires. Following gene introduction into T-cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize non-cognate epitopes from alternative source proteins. Notably, this TCR mediated killing of three-dimensional tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T-cells as a treatment for the vast majority of TNBC patients.

17 June 2026
Verified
Other
Open access
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy van Brakel
Mandy van Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Top-ranked ROPN1/B peptides and their scores for immunogenicity, non-cross reactivity, HLA-A2 binding and immunogenicity.

17 June 2026
Verified
Other
Open access
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy van Brakel
Mandy van Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Expressions of ROPN1/B, NY-ESO1 and MAGE-A4 target antigens in healthy tissues, TNBC and other tumor types.